Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Get Alerts APLS Hot Sheet
Join SI Premium – FREE
WALTHAM, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will participate in the following investor conferences in March:
- Cowen 42nd Annual Health Care Conference: Fireside chat on Wednesday, March 9, 2022 at 12:50 p.m. ET.
- Oppenheimer 32nd Annual Healthcare Conference: Fireside chat on Wednesday, March 16, 2022 at 12:40 p.m. ET.
The conference events will be available via live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. Replays of the webcasts will be available for 90 days following the event.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. For more information, please visit www.apellis.com.
Investor Contact:
Meredith Kaya
[email protected]
617.599.8178
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Steelworkers back Canada holding the line on trade, call for a stronger response to protect Canadian jobs and industry
- Crypto Update Flashes the Bottom Signal and Pepeto Is Where Early Money Is Rushing
- Watershed Roofing Inc. Expands Roofing and Exterior Services Across British Columbia
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share